Bayer could be the next in line to spin-off its Consumer Health business. Kicking off a company-wide strategic review, new CEO Bill Anderson has promised investors that “nothing is off the table.”
Speaking as the German firm reported its Q2 results, Anderson – who took the helm on 1 June – said he was making a full assessment of Bayer’s strategic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?